Page 11 - Read Online
P. 11

Rutledge et al. Hepatoma Res 2019;5:31  I  http://dx.doi.org/10.20517/2394-5079.2019.19                                          Page 5 of 12






                                                      n






                                                      n







                                                       n                             n







                                                       n                                n
                                                                                               n
                                                                                                 n

                                                                                     n
                                                                                                n

                                                                                              n
                                                       n
                                                                                                     n


                                                                                               n







               Figure 1. PRISMA study flow chart. HCC: hepatocellular carcinoma.

               (95%CI: 3.77,16.22). Their IFN-treated counterparts who did not clear HCV had a de novo HCC incidence
               rate of 2.94/100py (95%CI: 1.88, 4.04) [Figure 2].


               We performed an additional smaller meta-analysis of the five studies that performed multivariate-adjusted
               hazard ratios (adjusting for gender, baseline cirrhosis, and patient age), and found no increased risk of de novo
               HCC in patients treated with DAA compared to the IFN-treated population: unadjusted HR of 1.76 (95%CI:
               0.001, 4.70) and adjusted HR of 0.58 (95%CI: 0.20, 1.07) [Figure 3]. When we looked at de novo rates in the
               second year after treatment with DAAs, we found a similar incidence rate of 0.88 per 100py, (95%CI: 0.0001,
               1.94) compared to a second-year annualized incidence rate of 0.55 per 100py, (95%CI: 0.03, 1.29) in IFN-
               treated patients. We then excluded any cases of de novo HCC occurring within six months after end-of-
               treatment and obtained an incidence rate of 1.12 per 100py (95%CI: 0.43,1.98) in the DAA group and a
               higher incidence rate of 3.01 per 100py (95%CI: 0.033, 9.02) in the IFN group, which did not reach statistical
               significance.
   6   7   8   9   10   11   12   13   14   15   16